Because the application of oncolytic virus therapy in cancer has been another major milestone, following the success of ICB therapy, and has achieved surprising efficacy in multiple cancers (203, 204), we may focus on CLRs as novel potential targets in oncolytic virus therapy in bladder cancer. The gene discussed is LARS1; the disease is urinary bladder cancer.